Abstracts tagged "outcomes and rheumatoid arthritis (RA)"

Abstract Number: 1520 • 2016 ACR/ARHP Annual Meeting
RA Flare after Total Hip and Total Knee Arthroplasty: Preliminary Outcomes at 1 Year
Susan M. Goodman¹, Susan J. Bartlett², Ryan Cummings³, Kathleen Andersen³, Edward F. DiCarlo⁴, Mark P. Figgie⁵, Laura T. Donlin⁶, Dana E. Orange⁷ and Vivian P. Bykerk⁸, ¹Medicine, Hospital for Special Surgery, New York, NY, ²Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ³Hospital for Special Surgery, New York, NY, ⁴Laboratory Medicine, Hospital for Special Surgery, New York, NY, ⁵Orthopaedics, Hospital for Special Surgery, New York, NY, ⁶Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY, ⁷Rheumatology, Hospital for Special Surgery, New York, NY, ⁸Divison of Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: Post-op flares are frequent for RA patients after total hip (THA) and total knee arthroplasty (TKA), when medications are discontinued to mitigate infection…
Abstract Number: 2231 • 2016 ACR/ARHP Annual Meeting
Change in Health Care Utilization after Etanercept Initiation in Patients with Rheumatoid Arthritis
Neil Accortt¹, Jennifer Schenfeld^2,3, Eunice Chang⁴, Elya Papoyan⁴ and Michael S. Broder⁴, ¹Center for Observational Research, Amgen, Inc, Thousand Oaks, CA, ²Docs Global, Inc, North Wales, PA, ³Amgen Inc., Thousand Oaks, CA, ⁴Partnership for Health Analytic Research, LLC, Beverly Hills, CA
Background/Purpose: Patients with rheumatoid arthritis (RA) have higher healthcare utilization (HCU) and costs than patients without RA1. Evidence is mixed as to the impact of…
Abstract Number: 2468 • 2016 ACR/ARHP Annual Meeting
Assessment of the American-English Version of the French FLARE in Rheumatoid Arthritis
Nashla Barroso¹, Thasia G Woodworth², Francis Guillemin³, Daniel E. Furst⁴, Jenny Brook⁵, Suzanne Kafaja⁶, David Elashoff⁵, Bruno Fautrel⁷ and Veena Ranganath⁸, ¹Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²Leading Edge Clinical Research, Stuart, FL, ³CHRU Nancy, Clinical Epidemiology and Evaluation, Université de Lorraine, Paris Descartes University, APEMAC, EA 4360, Nancy, France, ⁴David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁵Medicine, David Geffen School of Medicine, Los Angeles, CA, ⁶Medicine/Rheumatology, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁷Rheumatology, Pitié Salpêtrière Hospital, Paris, France, ⁸Cumberland Valley Rheumatology, P.C., Chambersburg, PA
Background/Purpose: Due to the lack of consensus of the definition of a rheumatoid arthritis (RA) flare, the French “FLARE” (FLare Assessment in RA) instrument was…
Abstract Number: 3013 • 2016 ACR/ARHP Annual Meeting
Dose Reduction or Discontinuation of Biological Therapy in Patients with Rheumatoid Arthritis in Remission – 1-Year Results of a Guideline-Directed Longitudinal Cohort Study
Cecilie Heegaard Brahe¹, Simon Krabbe², Mikkel Østergaard³, Henrik Rogind⁴, Hanne Slott Jensen³, Annette Hansen⁵, Jesper Nørregaard⁶, Søren Jacobsen⁷, Lene Terslev⁸, Tuan K. Huynh⁹, Dorte Vendelbo Jensen⁵, Natalia Manilo¹⁰, Karsten Heller Asmussen¹¹, Per Brown-Frandsen⁷, Mikael Boesen¹², Zoreh Rastiemadabadi¹³, Daniel Glinatsi¹⁴, Lone Morsel-Carlsen¹⁵, Jakob M. Møller¹⁶, Niels Steen Krogh¹⁷ and Merete Lund Hetland^3,18, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Glostrup, Denmark, ²Center for Rheumatology and Spine diseases, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Glostrup, Denmark, ³Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark, ⁴Center for Rheumatology and Spine Diseases, Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, University of Copenhagen, Denmark, Glostrup, Denmark, ⁵DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Copenhagen, Denmark, ⁶Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ⁷Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, University of Copenhagen, Denmark, Glostrup, Denmark, ⁸Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Copenhagen Center for Arthritis Research (COPECARE), Copenhagen, Denmark, ⁹Department of Rheumatology, Copenhagen University Hospital at Nordsjælland, Denmark, Hillerød, Denmark, ¹⁰The DANBIO registry and the Danish Departments of Rheumatology, Copenhagen, Denmark, ¹¹Department of Rheumatology, Copenhagen University Hospital at Frederiksberg-Bispebjerg, Denmark, Frederiksberg, Denmark, ¹²Frederiksberg Hospital, Parker Institute, Frederiksberg, Denmark, ¹³Department of Radiology, Frederiksberg Hospital, Frederiksberg, Denmark, ¹⁴Center for Rheumatology and Spine Diseases, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, Glostrup, Denmark, ¹⁵Department of Radiology, Rigshospitalet, Copenhagen, Denmark, ¹⁶Department of Radiology, Copenhagen University Hospital Herlev and Gentofte, Herlev, Denmark, ¹⁷Zitelab, Frederiksberg, Denmark, ¹⁸Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark
Background/Purpose: Dose tapering in patients in remission has previously proven promising in randomized controlled trials. However, systematic implementation in clinical practice is lacking. A new…
Abstract Number: 1577 • 2015 ACR/ARHP Annual Meeting
Periodontal Evaluation Is Associated with Increased Likelihood of Achieving Low Disease Activity in Rheumatoid Arthritis with Methotrexate
Melanie Rohr¹, James R. O'Dell¹, Abhijeet Danve², Harlan Sayles¹, Geoffrey M. Thiele³, Jeffrey Payne⁴ and Ted R. Mikuls⁵, ¹University of Nebraska Medical Center, Omaha, NE, ²Rheumatology, University of Nebraska Medical Center, Omaha, NE, ³Research Services 151, Omaha VA Medical Center, Omaha, NE, ⁴College of Dentistry, University of Nebraska Medical Center, Lincoln, NE, ⁵Medicine, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatoid arthritis (RA) outcomes have improved substantially due to the development of new drug therapies, but also due to emphasis on early aggressive MTX…
Abstract Number: 2590 • 2015 ACR/ARHP Annual Meeting
Anti-Citrullinated Protein Antibody and Radiographic Disease Progression in Rheumatoid Arthritis
Brian Coburn¹, Geoffrey M. Thiele¹, Michael J. Duryee², Fang Yu³, Harlan Sayles⁴, Jeremy Sokolove⁵, WH Robinson⁶, Alan Erickson⁷, Mary Brophy⁸, James R. O'Dell¹ and Ted R. Mikuls¹, ¹Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ²Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ³Public Health, University of Nebraska Medical Center, Omaha, NE, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Stanford University, Palo Alto, CA, ⁶VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ⁷University of Nebraska College of Medicine and VA Nebraska Western Iowa Health Care System, Omaha, NE, ⁸VA Boston Heathcare System, Boston, MA
Background/Purpose: Anti-citrullinated protein antibody (ACPA) positivity is associated with more rapid radiographic progression in rheumatoid arthritis (RA). A majority of prior studies, however, have assessed…
Abstract Number: 2671 • 2015 ACR/ARHP Annual Meeting
Male Gender and Higher Hemoglobin Predict Response to Methotrexate in Rheumatoid Arthritis
Abhijeet Danve¹, Harlan Sayles², Ted R. Mikuls³ and James R. O'Dell², ¹Internal Medicine - Rheumatology, University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³Internal Medicine, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Methotrexate (MTX) is routinely used as the first-line drug for rheumatoid arthritis (RA). About 1 in 3 RA patients achieve excellent RA control with…
Abstract Number: 2774 • 2015 ACR/ARHP Annual Meeting
Longterm Outcome of Patients Switched from Iv to Sc Formulation of Abatacept: A Monocentric Study
Rossella Reggia¹, Ilaria Cavazzana¹, Angela Tincani² and Franco Franceschini¹, ¹Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ²Rheumatology and Clinical Immunology Unit, Spedali Civili and University of Brescia, Brescia, Italy
Background/Purpose: Abatacept is a selective T cell costimulation modulator indicated for active Rheumatoid Arthritis (RA). Since August 2013, in Italy, the drug has also been…
Abstract Number: 467 • 2015 ACR/ARHP Annual Meeting
Clinical Outcomes of Patients with Active Rheumatoid Arthritis with Normal Acute-Phase Reactant Values
In Je Kim¹, Hyesook Park², Sang-Cheol Bae³ and Jisoo Lee⁴, ¹Division of Rheumatology, Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, South Korea, ²Dep of Preventive medicine, Ewha Womans University School of medicine, Seoul, South Korea, ³Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁴Internal Medicine, Ewha Womans Univeristy School of Medicine, Seoul, South Korea
Background/Purpose: Despite high clinical disease activity measured by joint counts and global assessments, some patients with active rheumatoid arthritis (RA) have normal acute-phase reactant (APR)…
Abstract Number: 469 • 2015 ACR/ARHP Annual Meeting
Window of Opportunity to Achieve Major Outcomes in Early Rheumatoid Arthritis Patients: How Persistence with Therapy Matters
Virginia Pascual-Ramos¹ and Irazú Contreras-Yáñez², ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Inmunología y Reumatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: The window of opportunity concept states that there are superior clinical responses and the potential for remission, when patients with rheumatoid arthritis (RA) are…
Abstract Number: 575 • 2015 ACR/ARHP Annual Meeting
Predictive Factors for Achieving Low Disease Activity at 52 Weeks after Switching from Tumor Necrosis Factor Inhibitors to Abatacept: Results from a Multicenter Observational Cohort Study of Japanese Patients
Toshihisa Kojima¹, Nobunori Takahashi¹, Koji Funahashi¹, Shuji Asai², Toki Takemoto², Nobuyuki Asai³, Tatsuo Watanabe², Naoki Ishiguro⁴ and TBCR Study Group, ¹Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ²Nagoya University Hospital, Nagoya, Japan, ³Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ⁴Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan
Background/Purpose: : Currently, there is no clarity regarding which biologic to switch to when patients fail to respond to TNF inhibitors (TNFis). Detailed information for…
Abstract Number: 1563 • 2015 ACR/ARHP Annual Meeting
Dyslipidemia and Hyperglycemia, Two Cardiometabolic Parameters, Independently Predict Poor Outcome in Early Rheumatoid Arthritis: Results from Espoir Cohort
Claire I. Daien¹, Jeremie Sellam², Nathalie Rincheval³, Bruno Fautrel⁴, Alain Saraux⁵, Francis Berenbaum⁶, Jacques Morel¹, Jean-Pierre Daures⁷ and Bernard Combe⁸, ¹Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France, ²Department of Rheumatology, Assistance Publique – Hôpitaux de Paris, Saint-Antoine Hospital, Paris, France, ³Biostatistic, EA 2415, Epidemiology unit, Montpellier, France, ⁴Rheumatology, AP-HP Pitié-Salpêtrière Hospital / Pierre and Marie Curie University Paris 6 GRC-08 (EEMOIS), Paris, France, ⁵Rheumatology Department, CHU de la Cavale Blanche, Brest Cedex, France, ⁶Rheumatology and Paris VI University, Saint-Antoine Hospital, Paris, France, ⁷Biostatistic, EA 2415 Epidemiology unit, Montpellier, France, ⁸Rheumatology, Hopital Lapeyronie, Montpellier, France
Background/Purpose: Previous studies showed that obesity in patients with rheumatoid arthritis (RA) is associated with higher disease activity. Beyond obesity, cardiometabolic disturbances may impact the…
Abstract Number: 2401 • 2014 ACR/ARHP Annual Meeting
Interrupted and Delayed Care in First Nation Patients with Rheumatoid Arthritis: The Best Target for Therapy?
Liam O'Neil¹, Carol A. Hitchon², David B. Robinson³, Navjot Dhindsa¹, Hani El-Gabalawy³ and Christine A. Peschken⁴, ¹Medicine, University of Manitoba, Winnipeg, MB, Canada, ²Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ³Arthritis Centre, University of Manitoba, Winnipeg, MB, Canada, ⁴University of Manitoba, Canada, Winnipeg, MB, Canada
Background/Purpose: Severe disease and poor outcomes have been described in First Nation (FN) patients with Rheumatoid Arthritis (RA). We examined the contributions of interrupted and…
Abstract Number: 2390 • 2014 ACR/ARHP Annual Meeting
Determinants and Impact of Early Initiation of Disease-Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis
Chandana Keshavamurthy¹, Kevin Kuriakose², Deepak Chandra², Aneet Kaur², Horace Spencer² and Nasim A. Khan³, ¹Division of Rheumatology, University of Arkansas for Medical Sciences, Little Rock, AR, ²University of Arkansas for Medical Sciences, Little Rock, AR, ³Rheumatology, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, AR
Background/Purpose Early initiation of disease-modifying anti-rheumatic drug (DMARD) therapy is recommended to improve rheumatoid arthritis (RA) outcomes. The aim of this study was to determine…
Abstract Number: 1060 • 2014 ACR/ARHP Annual Meeting
Musculoskeletal Surgeries and Procedures in Patients with RA: Results from a UK Retrospective Study
H Cawston¹, F Bourhis¹, T Le² and E Alemao³, ¹OptumInsight, Nanterre, France, ²Bristol-Myers Squibb, Hopewell, NJ, ³Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Musculoskeletal surgeries and procedures substantially improve the quality of life of patients with RA, but represent an important burden in terms of medical costs.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].